Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells

References

• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/onci.23510; PMID: 23687621
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862 - 73; http://dx.doi.org/10.1038/nrc2763; PMID: 19935675
   PubMed Web of Science ®Google Scholar
• Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26:2243 - 54; http://dx.doi.org/10.1038/sj.onc.1210295; PMID: 17401433
   PubMed Web of Science ®Google Scholar
• Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, et al. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 2008; 68:3707 - 14; http://dx.doi.org/10.1158/0008-5472.CAN-07-6776; PMID: 18483253
   PubMed Web of Science ®Google Scholar
• Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One 2009; 4:e6819; http://dx.doi.org/10.1371/journal.pone.0006819; PMID: 19714248
   PubMed Web of Science ®Google Scholar
• Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D’Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10:1679 - 89; http://dx.doi.org/10.4161/cc.10.10.15642; PMID: 21508668
   PubMed Web of Science ®Google Scholar
• Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 2012; 131:E562 - 8; http://dx.doi.org/10.1002/ijc.26441; PMID: 21932419
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Casares N, Péquignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84:131 - 79; http://dx.doi.org/10.1016/S0065-2776(04)84004-5; PMID: 15246252
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146 - 52; http://dx.doi.org/10.1016/j.coi.2010.09.008; PMID: 20970973
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54 - 61; http://dx.doi.org/10.1038/nm1523; PMID: 17187072
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062 - 79; http://dx.doi.org/10.1038/emboj.2011.497; PMID: 22252128
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578 - 90; http://dx.doi.org/10.1038/emboj.2009.1; PMID: 19165151
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 2012; 7:e31732; http://dx.doi.org/10.1371/journal.pone.0031732; PMID: 22412839
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218 - 9; http://dx.doi.org/10.4161/onci.20428; PMID: 23170286
   PubMed Web of Science ®Google Scholar
• Biroccio A, Bufalo DD, Ricca A, D’Angelo C, D’Orazi G, Sacchi A, Soddu S, Zupi G. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther 1999; 6:1064 - 72; http://dx.doi.org/10.1038/sj.gt.3300935; PMID: 10455409
   PubMed Web of Science ®Google Scholar
• D’Avenia P, Porrello A, Berardo M, Angelo MD, Soddu S, Arcangeli G, Sacchi A, D’Orazi G. Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett 2006; 231:102 - 12; http://dx.doi.org/10.1016/j.canlet.2005.01.033; PMID: 16356835
   PubMed Web of Science ®Google Scholar
• Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733 - 7; http://dx.doi.org/10.1126/science.285.5434.1733; PMID: 10481009
   PubMed Web of Science ®Google Scholar
• Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191:411 - 6; http://dx.doi.org/10.1084/jem.191.3.411; PMID: 10662786
   PubMed Web of Science ®Google Scholar
• Blachère NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 2005; 3:e185; http://dx.doi.org/10.1371/journal.pbio.0030185; PMID: 15839733
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100 - 4; http://dx.doi.org/10.1158/1078-0432.CCR-09-2891; PMID: 20421432
   PubMed Web of Science ®Google Scholar
• Lippincott-Schwartz J, Yuan LC, Bonifacino JS, Klausner RD. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 1989; 56:801 - 13; http://dx.doi.org/10.1016/0092-8674(89)90685-5; PMID: 2647301
   PubMed Web of Science ®Google Scholar
• Zhang K, Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004; 279:25935 - 8; http://dx.doi.org/10.1074/jbc.R400008200; PMID: 15070890
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499 - 509; http://dx.doi.org/10.1038/cdd.2008.67; PMID: 18464797
   PubMed Web of Science ®Google Scholar
• Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8:413 - 5; http://dx.doi.org/10.4161/auto.19009; PMID: 22361584
   PubMed Web of Science ®Google Scholar
• Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2013; [Epub ahead of print] http://dx.doi.org/10.1038/cdd.2013.48; PMID: 23686135
   PubMed Web of Science ®Google Scholar
• Beyersmann D, Haase H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 2001; 14:331 - 41; http://dx.doi.org/10.1023/A:1012905406548; PMID: 11831463
   PubMed Web of Science ®Google Scholar
• Hainaut P, Milner J. A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53. Cancer Res 1993; 53:1739 - 42; PMID: 8467489
   PubMed Web of Science ®Google Scholar
• Méplan C, Richard M-J, Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 2000; 19:5227 - 36; http://dx.doi.org/10.1038/sj.onc.1203907; PMID: 11077439
   PubMed Web of Science ®Google Scholar
• Petersen TR, Dickgreber N, Hermans IF. Tumor antigen presentation by dendritic cells. Crit Rev Immunol 2010; 30:345 - 86; http://dx.doi.org/10.1615/CritRevImmunol.v30.i4.30; PMID: 20666707
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15:3 - 12; http://dx.doi.org/10.1038/sj.cdd.4402269; PMID: 18007663
   PubMed Web of Science ®Google Scholar
• Cirone M, Lucania G, Aleandri S, Borgia G, Trivedi P, Cuomo L, Frati L, Faggioni A. Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells. Immunol Lett 2008; 120:37 - 41; http://dx.doi.org/10.1016/j.imlet.2008.06.011; PMID: 18680763
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Trivedi P, Lucania G, Borgia G, Frati L, Faggioni A. Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK. Int J Immunopathol Pharmacol 2010; 23:1079 - 86; PMID: 21244757
   PubMed Web of Science ®Google Scholar
• Garufi A, Pistritto G, Ceci C, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D’Orazi G. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One 2012; 7:e48342; http://dx.doi.org/10.1371/journal.pone.0048342; PMID: 23144866
   PubMed Web of Science ®Google Scholar
• Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D’Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004; 293:311 - 20; http://dx.doi.org/10.1016/j.yexcr.2003.09.032; PMID: 14729469
   PubMed Web of Science ®Google Scholar
• Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D, D’Orazi G. Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med 2010; 48:1338 - 46; http://dx.doi.org/10.1016/j.freeradbiomed.2010.02.015; PMID: 20171273
   PubMed Web of Science ®Google Scholar